click enter text
full postview in-lin ep higher rev
report financi result wednesday open
compani higher revenu in-lin ep
guidanc lower revenu ep anticip
loxo acquisit lartruvo failur
small tweak forecast increas pt base higher
bodi report full analysi
inform stock cover see recent report
global pharmaceut outlook januari issu monthli
trade fundament data
upsid target
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
wednesday market open
report result higher revenu in-lin ep compar consensu
lower guidanc still includ elanco
announc plan divest elanco share exchang unexpect
overal impress report decent result revenu come stronger ep in-lin
technic small miss guidanc consensu surpris
encompass recent dilut loxo acquisit setback smaller cancer drug lartruvo
confer call major new revel much stori describ recent
alreadi dec analyst day guidanc first given loxo confer call
come long way last sever year upgrad stock heavili favor
pendulum clearli swung stock consensu buy re-launch wolf
late peer-perform rate feel risk reward evenli balanc
strong run throughout year howev back strong guidanc given decemb analyst day
long-term outlook better initi model leav well-posit compani
substanti exposur diabet revenu categori seem well-posit rel
peer also categori price competit meaning peer-perform rate
favor pre-dispos toward above-averag lt growth profil
term sale ep exhibit
revenu higher vs consensu growth primarili driven
trulic taltz basaglar slower eros ciali also contribut revenu
non-gaap ep in-lin vs consensu higher expect sg
due launch expens emgal main drag ep partial off-set lower expect
trulic higher consensu includ price declin
us mix-shift toward certain govern segment note trulic continu increas
share market ozemp launch
taltz higher vs consensu note patient afford
program lead increas volum
humalog higher vs consensu
term guidanc exhibit
revenu lower vs prior
non-gaap ep lower vs prior
page
 rais vs prior account incorpor
tax lower vs prior
long-term guidanc reiter oper margin least includ addit
impact divest elanco
pipelin noth new report
revenu increas ep increas
revenu estim decreas ep estim increas
depend year
ep compound-annual-growth-rate ep compound-annual-growth-rate increas repres peer
price target increas vs prior repres unchang
gener prepar remark note
oper readi effect full separ elanth compani plan offer exchang
offer sharehold exchang remain share share could begin
soon come day
report us volum growth diabet busi
 long take trulic benefit rewind uptak look like trulic continu
benefit market growth continu gain share sinc ozemp launch rewind
begin promot dataset new label
 attribut sequenti jardianc trend particularli bullish
jardianc due ada/aasd guidelin bullish stanc particularli jardianc
placement formulari access look market data run low-to-mid
nbrx share acceler double-digit given profil invest rel
competitor remain bullish jardianc place share leader
page
 see carolina data expect see top-line result quarter
 stanc rewind data even bullish dataset
 verzenio inventori impact long-term outlook million inventori impact quarter
work drive convers also look forward intern launch note good
uptak europ japan drive verzenio util poor prognosi patient liver metastas
 upcom readout percentag patient candid addit readout
medic meet loretto studi previous saw respons rate
depend tumor type stay therapi incid rate ret fusion happen
lung cancer papillari medullari thyroid expect see strong penetr
long durabl respons
 comment loxo manag sale estim vitrakvi soon tell initi
 test ret tyk mutat partner laboratori pathologist drive test
see uptak academ cancer center help drive adopt test
 monarch-hr phase ii read year may inform phase success
 gener sens baricitinib ad data compar dupix report posit data
studi read year full data packag kol see market like psoriasi
market year ago there larg opportun first oral note ad patient
moder sever
 baricitinib hit statist signific ad dosag arm mg meet primari endpoint
mg arm mg mg met sole primari endpoint iga also met
secondari endpoint data avail met secondari endpoint miss
 think uptak mg olumi see strong uptak across globe
similar efficaci mg price discount market leader access
issu continu look mg dose across differ indic
 clarif baricitinib atop dermat endpoint one primari endpoint number
secondari endpoint present futur confer
report nbrx share end note best-in-class payer coverag base
page
 might tanezumab rem program construct impact launch reiter
confid efficaci risk rpoa look total data unmet need continu
see compel benefit tanezumab prematur discuss possibl rem see
lt safeti data mani oa patient similar trial popul
 updat emgal paid prescript ratio current expect million patient elig cgrp
current see paid prescript market split equal primari care neurologist
mid-level current look nbrx januari launch new dtc campaign drive
uptak see differenti efficaci reduct devic
 lasmiditan affect cgrp expect regulatori action million migrain
million undiagnos million acut migrain there huge need prophylaxi
acut treatment market may also overlap patient dont achiev full relief
cgrp mani acut patient fallen due lack efficaci cant toler treatment
lasmiditan offer patient relief
 see net price evolv emgal cgrp best access base
three major formulari decis one small region payer deni formulari coverag nbrx
rate exclud sampl initi expect market continu grow although switch
retail made volum growth look bit flat despit underli demand
expect mid-single-digit price declin us expect remov safe harbor provis
would repres meaning chang systemit could win patient lower cost
counter take highli rebat product like insulin push manufactur demonstr valu
product partner payer may also remov rebat wall artifici barrier competit
think could also resolv issu sick subsid well
 expect exclus contract end look statu quo expect continu
trend come exclus contract payer attempt restrict util
extract rebat uncertainti remain around new propos rule need see play
 price pressur difficult specul current especi given number current rule
propos drug price innovation-bas strategi like lli way weather on-going price
pressur administr concern govern payer commerci recent idea
pass rebat part plan consist lli previou polici posit
 second ndc brand strategi medicar formulari commerci viabl continu look
avail strategi product-by-product situat
ww growth driven volum growth off-set price us volum grew off-set price
declin due chang rebat estim trulic growth government segment driven basaglar
uptak part use patient access program taltz humalog
page
ep guidanc cut driven cent lartruvo cent inclus loxo oncolog
continu includ cent declin non-controlling-interest pharma ep guidanc
issu execut offer know mani share retir
reiter confid target
 contribut on-going clinic program guidanc guidanc rang contempl
success late stage program drove guidanc increas line item mani
trial affect guidanc theyr posit revenu compound-annual-growth-rate depend
one clinic program success
 driver mid-single-digit declin price medicar donut hole expans
drive point declin new item rest declin driven normal dynam
includ expand use patient access program product mix maintain access competit
 oper margin dynam remov repres oper margin
improvementoutsid expect mid-single-digit revenu growth expens control drive
remaind margin expans
 balanc rel peer reach oper margin wont nail
long-term margin target dont visibl opportun new product line-up
howev drive continu margin expans also note continu balanc across
intern extern invest top-line grow expect see better gross margin sg
percentag sale determin opportun pipelin
 bd capac particular ta prioriti see good cash flow year go forward
see real financi constraint investor expect continu look immunolog
oncolog given avail opportun theyr open asset creat valu
exhibit show compani report actual result vs estim consensu
page
exhibit result vs wr estim consensu
exhibit summar lli financi guidanc vs estim
page
exhibit guidanc vs wr estim old new
exhibit captur chang forecast
page
bgross marginapprox bother meffect tax rateapprox guidancewr estim
exhibit chang wr model
exhibit show incom statement product revenu summari balanc sheet/cash flow
page
page
incom statement incom loss cont op dilut share growth outstand
page
product revenu growth share tradjenta basaglar biosimilar share jardianc trulic women endocrinolog growth diabet alimta cyramza gastric lartruvo olaratumab verzenio abemaciclib erbitux total prasugrel share total total primari taltz ixekizumab olumi baricitinib jak tanezumab anti-ngf pain galcanezumab anti-cgrp migrain total specialti total earli stage factor- total anim total
exhibit wr eli lilli balanc sheet cash flow statement
page
summari statement incom reconcil incom tax cash provid oper tax chang oper asset defer compens impair net in-process technolog net cash provid sale in-process product paid acq/loan cash provid use invest stock capit chang short term issuanc long term repay long-term cash provid use financ exchang rate cash increas decreas end balanc sheet cash equival short term properti plant goodwil current term non-curr paid-in comprehens treasuri stock sharehold liabil sharehold
